Bad Vilbel, December 2, 2019 – The STADA Group announced today that it is acquiring the pharmaceutical business of Biopharma, one of the key pharmaceutical producers in Ukraine. This also includes production facilities in the city of Bila Tserkva, in the Kyiv region.
As a result of this acquisition, STADA has made one of the largest financial investments in the Ukrainian pharmaceutical sector to date and one of the biggest recent foreign investments in this country. ”We see great potential in the Ukrainian market. With this acquisition, we will become an important player in the Ukrainian pharma market with a strong local production footprint,” emphasizes STADA CEO Peter Goldschmidt.
Konstantin Efimenko, Biopharma’s Managing Partner: “Biopharma is a leading pharmaceutical company founded over 100 years ago and expanding rapidly since 2014, building two state-of-the-art, GMP-certified facilities in Bila Tserkva. We offer high-quality engineering, a skilled, professional team and high production standards monitored through international audits. Attracting such a high-quality European investor demonstrates confidence in our employees and capabilities, and will reinforce our ability to deliver high-quality and innovative products to patients. Together with my partner Mr. Vasyl Khmelnytskiy and financial investors, I will focus on Biopharma’s plasma business, leveraging our new plasma fractionation plant, developing a network of modern blood collection centers and expanding our presence on international markets.”
STADA’s Ukrainian business will be headed by the newly appointed General Manager Borys Labensky.
The acquisition is subject to customary conditions precedent, including merger clearance in Ukraine, and is expected to close till the end of 2019.
Source: https://www.stada.com
Свежие комментарии